Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
The discovery of the tumor-inhibitory properties of asparaginase (ASNase) began in the early 1950s with the observation that guinea pig serum-treated lymphoma-bearing mice underwent rapid and often complete regression. About 4000 cases of acute lymphoblastic leukemia (ALL) are diagnosed very year in the US and many more through out the world. The majority of these cases are in children and young adults, making ALL the most common form of malignancy in these age groups. The treatment protocols of ALL are complex and use 6-12 drugs. Consequently, the improvement in the protocol design has improved significantly the success rate for long-term event-free survival in the past 20-30 years, which is now approximately 75% for patients afflicted with the higher risk ALL features and just above this percentage for patients with standard or good features. Despite this success, approximately 15% of patients die from ALL, making leukemic relapse the most common cause of treatment failure in pediatric oncology. ASNases have been the cornerstone of ALL therapies since the late 1970s. Native or pegylated L-asparaginase (ASNase or PEG-ASNase) are highly specific for the deamination of L-asparagine (Asn) to aspartic acid and ammonia. Depletion of Asn leads to a nutritional deprivation and inhibition of protein biosynthesis, resulting in apoptosis in T-lymphoblastic leukemias, which require Asn from external sources. The reactions of the host exposed to repeated ASNase treatments as well as the up-regulation of the mammalian enzymes to overcome the ASN-depletion toxic condition are of significant importance and may make us relearn the lessons on this important antileukemic drug.
Avramis
Vassilios I
VI
CHLA, Department of Pediatrics, Division of Hematology/Oncology, Keck School of Medicine, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA. vavramis@chla.usc.edu
Tiwari
Prakash Nidhi
PN
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D001215:Asparaginase / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D011092:Polyethylene Glycols / Q000737:chemistry*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism*
D000970:Antineoplastic Agents; D004337:Drug Carriers; D011092:Polyethylene Glycols; D001215:Asparaginase
Int Arch Allergy Appl Immunol. 1971;40(3):463-9
4993767
Leuk Lymphoma. 1993;10 Suppl:147-50
8481663
Leukemia. 2003 Nov;17(11):2254-6
14523472
J Biol Chem. 1976 Sep 10;251(17):5375-80
956189
Semin Oncol. 1982 Mar;9(1):5-13
6461924
Arch Biochem Biophys. 1964 May;105:450-2
14186753
Cancer. 1970 Feb;25(2):241-3
4905151
J Natl Cancer Inst. 1965 Dec;35(6):967-74
5856684
Cancer Res. 1966 Feb;26(2):208-11
5903173
Proc Natl Acad Sci U S A. 1966 Nov;56(5):1516-9
5339624
J Bacteriol. 1974 Feb;117(2):593-600
4590479
Cancer Chemother Pharmacol. 2002 Aug;50(2):117-20
12172975
J Exp Med. 1963 Jul;118:99-120
14015821
Biochim Biophys Acta. 1975 Feb 24;383(1):30-9
1173050
J Clin Oncol. 2005 Nov 1;23(31):7936-41
16258093
J Exp Med. 1953 Dec;98(6):565-82
13109110
Cancer Res. 1979 Oct;39(10):3893-6
383278
Eur J Biochem. 1996 Oct 1;241(1):201-7
8898907
J Bacteriol. 1976 Feb;125(2):719-27
1107330
Lancet. 1968 Oct 5;2(7571):776-7
4175572
N Engl J Med. 2004 Aug 12;351(7):657-67
15306667
Proc Soc Exp Biol Med. 1965 Jun;119:325-7
14328879
J Exp Med. 1966 Jan 1;123(1):55-74
5902571
Blood. 2001 Mar 1;97(5):1211-8
11222362
Blood. 2000 Sep 1;96(5):1709-15
10961868
Clin Pharmacokinet. 2005;44(4):367-93
15828851
Br J Haematol. 2005 Dec;131(5):579-87
16351633
Drugs Aging. 2005;22(12):983-1012
16363884
Cancer Res. 1967 Dec;27(12):2619-31
5237354
Anticancer Res. 2004 Mar-Apr;24(2C):1121-5
15154634
Med Pediatr Oncol. 2002 May;38(5):310-6
11979454
Pediatr Blood Cancer. 2006 Aug;47(2):141-6
16425271
Cancer Chemother Pharmacol. 1989;24(4):203-10
2473850
J Clin Oncol. 1993 Sep;11(9):1780-6
8355045
Clin Cancer Res. 2004 Aug 15;10(16):5335-41
15328169
Mol Cancer Ther. 2005 Dec;4(12):2008-15
16373716
Blood. 2002 Mar 15;99(6):1986-94
11877270
Br J Haematol. 2001 Dec;115(4):983-90
11843837
Indian J Cancer. 2005 Apr-Jun;42(2):65-9
16141504
Cancer Treat Rep. 1981;65 Suppl 4:111-4
7049374